These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21760530)

  • 21. Immunomodulation of Japanese encephalitis vaccine through CpG oligodeoxynucleotides in mice.
    Sidhapuriwala JN; Sivalingam SP; Lu J; Moochhala SM
    Scand J Immunol; 2006 Oct; 64(4):370-5. PubMed ID: 16970676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts.
    Balsari A; Tortoreto M; Besusso D; Petrangolini G; Sfondrini L; Maggi R; Ménard S; Pratesi G
    Eur J Cancer; 2004 May; 40(8):1275-81. PubMed ID: 15110894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
    Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
    Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model.
    Hamzah J; Altin JG; Herringson T; Parish CR; Hämmerling GJ; O'Donoghue H; Ganss R
    J Immunol; 2009 Jul; 183(2):1091-8. PubMed ID: 19561111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma.
    Sorrentino R; Morello S; Forte G; Montinaro A; De Vita G; Luciano A; Palma G; Arra C; Maiolino P; Adcock IM; Pinto A
    Am J Respir Crit Care Med; 2011 May; 183(10):1369-79. PubMed ID: 21278302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
    Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
    Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
    Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model.
    Heckelsmiller K; Rall K; Beck S; Schlamp A; Seiderer J; Jahrsdörfer B; Krug A; Rothenfusser S; Endres S; Hartmann G
    J Immunol; 2002 Oct; 169(7):3892-9. PubMed ID: 12244187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N; Mukherjee S; Das L; Das PK
    Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
    Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
    BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
    Fu X; Nakamori M; Tao L; Amato R; Zhang X
    Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
    VanOosten RL; Griffith TS
    Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity.
    Whitmore MM; DeVeer MJ; Edling A; Oates RK; Simons B; Lindner D; Williams BR
    Cancer Res; 2004 Aug; 64(16):5850-60. PubMed ID: 15313929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.
    Heckelsmiller K; Beck S; Rall K; Sipos B; Schlamp A; Tuma E; Rothenfusser S; Endres S; Hartmann G
    Eur J Immunol; 2002 Nov; 32(11):3235-45. PubMed ID: 12555669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9.
    Aurisicchio L; Peruzzi D; Conforti A; Dharmapuri S; Biondo A; Giampaoli S; Fridman A; Bagchi A; Winkelmann CT; Gibson R; Kandimalla ER; Agrawal S; Ciliberto G; La Monica N
    Clin Cancer Res; 2009 Mar; 15(5):1575-84. PubMed ID: 19240169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
    Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
    J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noninvasive and efficient transdermal delivery of CpG-oligodeoxynucleotide for cancer immunotherapy.
    Kigasawa K; Kajimoto K; Nakamura T; Hama S; Kanamura K; Harashima H; Kogure K
    J Control Release; 2011 Mar; 150(3):256-65. PubMed ID: 21256903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.